Cargando…

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

Detalles Bibliográficos
Autores principales:	Heuck, C J, Qu, P, van Rhee, F, Waheed, S, Usmani, S Z, Epstein, J, Zhang, Q, Edmondson, R, Hoering, A, Crowley, J, Barlogie, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274609/ https://www.ncbi.nlm.nih.gov/pubmed/25079174 http://dx.doi.org/10.1038/leu.2014.232

Ejemplares similares

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma
por: Khan, R, et al.
Publicado: (2015)

The Clinical Value of Molecular Subtyping Multiple Myeloma Using Gene Expression Profiling
por: Weinhold, N, et al.
Publicado: (2015)

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)
por: Papanikolaou, X, et al.
Publicado: (2016)

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with Total Therapy protocols
por: Usmani, Saad Z, et al.
Publicado: (2012)

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma
por: Hu, Bo, et al.
Publicado: (2013)

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma
por: Papanikolaou, X, et al.
Publicado: (2015)

An Evaluation of Gene Set Analysis for Biomarker Discovery with Applications to Myeloma Research
por: Qu, Pingping, et al.
Publicado: (2017)

SVMRFE based approach for prediction of most discriminatory gene target for type II diabetes
por: Kumar, Atul, et al.
Publicado: (2017)

Therapy-Related Myeloid Malignancies in Myeloma
por: Papanikolaou, X., et al.
Publicado: (2011)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015)

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use
por: van Laar, Ryan, et al.
Publicado: (2014)

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis
por: Papanikolaou, Xenofon, et al.
Publicado: (2014)

End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
por: Hoering, Antje, et al.
Publicado: (2017)

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Inhibiting MEK in MAPK pathway-activated myeloma
por: Heuck, C J, et al.
Publicado: (2016)

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
por: Bam, R, et al.
Publicado: (2014)

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols
por: Singh, Zeba N, et al.
Publicado: (2015)

Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow
por: Bam, Rakesh, et al.
Publicado: (2015)

Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia
por: Atrash, Shebli, et al.
Publicado: (2017)

Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat
por: Stein, Caleb K, et al.
Publicado: (2015)

Directly Discriminatory Algorithms
por: Adams‐Prassl, Jeremias, et al.
Publicado: (2022)

The discriminatory power of the T cell receptor
por: Pettmann, Johannes, et al.
Publicado: (2021)

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
por: Usmani, Saad Z., et al.
Publicado: (2018)

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434
por: Srkalovic, Gordan, et al.
Publicado: (2014)

Use of relevancy and complementary information for discriminatory gene selection from high-dimensional gene expression data
por: Haque, Md Nazmul, et al.
Publicado: (2021)

Anti-discriminatory counselling practice /
Publicado: (2003)

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
por: Durie, Brian G. M., et al.
Publicado: (2020)

Vesicles carry most exocyst subunits to exocytic sites marked by the remaining two subunits, Sec3p and Exo70p
por: Boyd, Charles, et al.
Publicado: (2004)

Discriminatory power of RNA family models
por: zu Siederdissen, Christian Höner, et al.
Publicado: (2010)

Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
por: Van Ness, Brian, et al.
Publicado: (2008)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
por: Davies, Faith E., et al.
Publicado: (2018)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes
por: Barfeld, Stefan J, et al.
Publicado: (2014)

Identification of discriminatory antibiotic resistance genes among environmental resistomes using extremely randomized tree algorithm
por: Gupta, Suraj, et al.
Publicado: (2019)

Regulating the discriminatory response to antigen by T-cell receptor
por: Gangopadhyay, Kaustav, et al.
Publicado: (2022)

Discriminatory punishment undermines the enforcement of group cooperation
por: Molenmaker, Welmer E., et al.
Publicado: (2023)

geneCommittee: a web-based tool for extensively testing the discriminatory power of biologically relevant gene sets in microarray data classification
por: Reboiro-Jato, Miguel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s2ohpbkub8m9l0k86mdhdpoqvp